All AbMole products are for research use only, cannot be used for human consumption.
Empesertib (BAY1161909) is an orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase (IC50 of < 1 nM), with potential antineoplastic activity. BAY1161909 also shows anti-tumor effect, suppressing the proliferation of Hela cells, with an IC50 of < 400 nM. The Mps1 kinase inhibitor Empesertib (BAY1161909) binds to and inhibits the activity of Mps1, it causes inactivation of the spindle assembly checkpoint (SAC), accelerated mitosis, chromosomal misalignment, chromosomal missegregation, mitotic checkpoint complex destabilization, and increased aneuploidy.
| Molecular Weight | 559.61 |
| Formula | C29H26FN5O4S |
| CAS Number | 1443763-60-7 |
| Solubility (25°C) | DMSO ≥ 24 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Serine/Threonine Protease Products |
|---|
| PMSF
PMSF is an irreversible serine/cysteine protease inhibitor. PMSF is commonly used in the preparation of cell lysates. |
| Aprotinin
Aprotinin is a small protein serine protease inhibitor which is used to reduce perioperative blood loss and transfusion. |
| AEBSF HCl
AEBSF HCl is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, plasmin, thrombin, and trypsin. |
| Nafamostat Mesylate
Nafamostat Mesylate is a synthetic serine protease inhibitor with concomitant anticoagulant activity. |
| UKI-1
UKI-1 is a novel synthetic inhibitor of the urokinase-type plasminogen activator, which inhibits the invasive capacity of carcinoma cells with a Ki of 0.41 μM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
